Piper Sandler analyst David Amsellem maintained a Hold rating on Viatris (VTRS – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $11.00.
Amsellem covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Alkermes, and Supernus Pharmaceuticals. According to TipRanks, Amsellem has an average return of -2.4% and a 41.85% success rate on recommended stocks.
In addition to Piper Sandler, Viatris also received a Hold from Goldman Sachs’s Nathan Rich in a report issued today. However, yesterday, Barclays maintained a Sell rating on Viatris (NASDAQ: VTRS).
See the top stocks recommended by analysts >>
The company has a one-year high of $12.10 and a one-year low of $8.13. Currently, Viatris has an average volume of 9.47M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Read More on VTRS:
- Viatris announces FDA acceptance of GA Depot NDA
- Viatris backs FY23 revenue $15.5B-$16B, consensus $15.6B
- Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
- VTRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Novartis weakness on Entresto patent ruling ‘seems overdone,’ says JPMorgan
